Penumbra Revenue Climbs 15.6% To $410.1 Million, But Net Income Slips To $42.3 Million
Selling costs outran sales, and with the Boston Scientific deal pending, the company will give no 2026 outlook and hold no call.
Penumbra, which makes devices that remove blood clots, posted third-quarter revenue of $410.1 million, up 15.6% from a year earlier, yet net income fell to $42.3 million from $45.9 million, the company said in an 8-K filed Thursday. Given the pending Boston Scientific acquisition, it will not provide full-year 2026 guidance or host a call on the results.
Costs grew faster than sales
Selling, general and administrative expenses rose to $204.2 million from $168.9 million a year earlier, and they include $7.1 million of expenses tied to the pending Boston Scientific deal. Total operating expenses reached $229.6 million, with research and development at $25.4 million.
Gross margin improved to 68.3%, up 0.5% from the year-earlier quarter, and operating income edged up to $50.7 million from $48.8 million. Net income per diluted share was $1.07, against $1.17 a year ago. The tax provision more than doubled to $14.0 million from $6.5 million.
For the first nine months, revenue was $1.17 billion, up 15.4%, while net income was $109.7 million, down from $130.3 million.
Thrombectomy leads, neuro rises
Penumbra develops, makes and sells devices that remove clots and treat other blood vessel conditions, with two product groups: thrombectomy, and embolization and access, which treats aneurysms and blocks vessels.
Thrombectomy revenue rose 18.1% to $279.2 million, led by U.S. venous thromboembolism sales, up 26.0%. Embolization and access climbed 10.8% to $131.0 million. U.S. neuro revenue rose 19.3% to $77.9 million.
By geography, U.S. revenue rose 17.9% to $324.2 million, while international sales rose 7.8% to $85.9 million.
No outlook while the deal is pending
The company's balance sheet showed $254.3 million in cash and $419.3 million in marketable investments at September 30, against $186.9 million and $357.9 million at the end of 2025.
Penumbra flagged the risk that the Boston Scientific acquisition will not close on the expected timeline or at all, including if required regulatory approvals are not obtained. It also cited possible employee departures and distraction of management during the pendency.
The quarter's results are the last the company will report with neither a call nor an outlook while regulators weigh the Boston Scientific deal.
Sources
- 8-K Filing — Penumbra Inc (PEN) — SEC EDGAR
- Exhibit pen-93026xexhibit991.htm — Penumbra Inc 8-K exhibit — SEC EDGAR
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results — prnewswire.com